GlobeNewsWire
18 Jun 2026, 02:10 UTC · 3h ago
Kuehn Law Encourages Investors of Corcept Therapeutics Incorporated to Contact Law Firm
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
GlobeNewsWire
18 Jun 2026, 02:10 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
2 claims · each scored for market impact
The FDA reportedly expressed concerns regarding the adequacy of Corcept Therapeutics' clinical development program for relacorilant. — FDA concerns regarding a lead product candidate significantly increase the probability of a drug rejection, directly impacting future revenue projections.
-0.80Corcept Therapeutics is facing a shareholder investigation into whether it failed to disclose material risks of FDA rejection for relacorilant. — Allegations of fiduciary breach and lack of transparency can lead to costly litigation and erode investor confidence in management.
-0.40Which stocks this story touches
The company is under investigation by a shareholder litigation law firm for potential breaches of fiduciary duties.
Continue reading
6 related stories
Top 1 mover · tap to explore
The company is under investigation for potential breach of fiduciary duties and failing to disclose FDA concerns regarding a lead product candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
GlobeNewsWire
3h ago
